Competing interests
CMO, cancer
ONCOLOGY, CANCER
JC has received honoraria from Pfizer, MSD Oncology, Pierre Fabre, and AstraZeneca; has acted in a Consulting or Advisory Role for AstraZeneca, Novartis, MSD, Cepheid and received Speakers' Bureau from Pfizer; has received research funding from Boehringer Ingelheim, Roche, Puma Biotechnology Regeneron, Novartis, MSD Oncology, BMS GmbH, and Co. KG; has received travel, accommodations, and expenses/conference registration from Roche, Daiichi Sankyo, AstraZeneca, MSD, Pfizer, Novartis, and Regeneron; is the Chief Medical Officer (CMO) at OncoMark Ltd and is employed with OncoAssure Ltd, and has associated stock and ownership interests with these entities. MSJM is a co-founder of and shareholder in TORL Biotherapeutics LLC and 1200 Pharma LLC. DMC has received research funding and research materials from Roche/Genentech, WntResearch; research materials from Sanofi; and has received research funding and consultancy fees from Puma Biotechnology, Inc. DMC, NG, NO, and JC report the filing of patent application WO2020011770A1—A method of predicting response to treatment in cancer patients. All other authors have declared no conflicts of interest.